A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.

By A. Bertotti, Giorgia Migliardi, F. Galimi, F. Sassi, Davide Torti, C. Isella, D. Corà, F. Di Nicolantonio, M. Buscarino, Consalvo Petti and 18 more. Cancer Discovery, 2011

894 citations recorded by the source corpus.

Subfields: Oncology

View Paper: https://www.semanticscholar.org/paper/c232affbe7d3d9e475cd5b20671d3e9bfc5845d8

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. J. Seoane
2. Carlos L. Arteaga
3. Fortunato Ciardiello
4. J. Engelman

Citations in the corpus

• Patient Derived Xenograft Models: An Emerging Platform for Translational Cancer Research (2014, methodology): “Furthermore, the analysis of clinically validated biomarkers, such as KRAS mutations, and resistance to EGFR inhibitors in PDX studies reached the same conclusions as clinical trials, as discussed in more detail below (28).”
• Comprehensive review of targeted therapy for colorectal cancer (2020, background): “By contrast, dual-targeted HER2 therapy was found to be promising in preclinical research.(118,123) In the phase II MyPathway trial, doublet treatment with trastuzumab, a classic HER2 inhibitor, and pertuzumab, a HER2 dimerization inhibitor, both of which are FDA approved in HER-positive breast canc”
• ERBB receptors: From oncogene discovery to basic science to mechanism-based cancer therapeutics (2014, methodology): “identified HER2 gene amplification as a predictor of resistance to cetuximab among KRASwild-type tumors (Bertotti et al., 2011).”
• ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. (2016, methodology): “Emerging data indicate that HER2 activating mutations or HER2 amplification may mediate in some instances resistance to EGFR antibodies [100, 113].”